Literature DB >> 32428324

Neurocognitive functioning in MDR-TB patients with and without HIV in KwaZulu-Natal, South Africa.

Suvira Ramlall1, Richard J Lessells2,3, Thirusha Naidu4, Sbusisiwe Sandra Mthembu5, Nesri Padayatchi3, Jonathan K Burns1,6, Andrew Tomita2,7.   

Abstract

OBJECTIVES: Optimising medication adherence is one of the essential factors in reversing the tide of a TB-HIV syndemic in sub-Saharan Africa, especially South Africa. Impairment in key neurocognitive domains may impair patients' ability to maintain adherence to treatment, but the level of cognition and its relationship to HIV status has not been examined in individuals with drug-resistant TB. We therefore investigated performance on several key neurocognitive domains in relationship to HIV status in a multidrug-resistant tuberculosis patients (MDR-TB) sample.
METHODS: We enrolled microbiologically confirmed MDR-TB inpatients at a TB-specialist referral hospital in KwaZulu-Natal province, South Africa. We collected cross-sectional data on sociodemographic, clinical and neurocognitive function (e.g. attention, memory, executive functioning, language fluency, visual-spatial, eye-hand coordination). For the primary analysis, we excluded participants with major depressive episode/substance use disorder (MDE/SUD). We fitted adjusted Poisson regression models to explore the association between HIV and neurocognitive function.
RESULTS: We enrolled 200 people with MDR-TB; 33 had MDE/SUD, and data of 167 were analysed (151 HIV+, 16 HIV-). The mean age of participants was 34.2 years; the majority were female (83%), and 53% had not completed secondary school. There was evidence of impaired neurocognitive functioning across all domains in both HIV+/- study participants. Based on the regression analyses, individuals with co-infection (MDR-TB/HIV+), as well as those who had longer duration of hospital stays experienced significantly lower cognitive performance in several domains. Poor cognitive performance was significantly related to older age and lower educational attainment. The presence of major depression or substance use disorders did not influence the significance of the findings.
CONCLUSIONS: Adults with MDR-TB have significant neurocognitive impairment, especially if HIV positive. An integrated approach is necessary in the management of MDR-TB as cognitive health influences the ability to adhere to chronic treatment, clinical outcomes and functionality.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  HIV; MDR-TB; South Africa; cognitive reserve; neuropsychological impairment

Mesh:

Year:  2020        PMID: 32428324      PMCID: PMC7686795          DOI: 10.1111/tmi.13444

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  17 in total

Review 1.  HIV-TB co-infection: epidemiology, diagnosis & management.

Authors:  S K Sharma; Alladi Mohan; Tamilarasu Kadhiravan
Journal:  Indian J Med Res       Date:  2005-04       Impact factor: 2.375

2.  Neurocognitive Impairment Risk Among Individuals With Multiple Drug-Resistant Tuberculosis and Human Immunodeficiency Virus Coinfection: Implications for Systematic Linkage to and Retention of Care in Tuberculosis/Human Immunodeficiency Virus Treatment.

Authors:  Andrew Tomita; Suvira Ramlall; Thirusha Naidu; Sbusisiwe Sandra Mthembu; Nesri Padayatchi; Jonathan K Burns
Journal:  J Nerv Ment Dis       Date:  2019-04       Impact factor: 2.254

3.  Effect of age and level of education on neurocognitive impairment in HIV positive Zambian adults.

Authors:  Norma Kabuba; J Anitha Menon; Donald R Franklin; Stian Lydersen; Robert K Heaton; Knut A Hestad
Journal:  Neuropsychology       Date:  2018-03-05       Impact factor: 3.295

4.  Screening for dementia in community-based memory clinics.

Authors:  Mark A Sager; Bruce P Hermann; Asenath La Rue; John L Woodard
Journal:  WMJ       Date:  2006-10

5.  Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.

Authors:  Christina M Marra; Yu Zhao; David B Clifford; Scott Letendre; Scott Evans; Katherine Henry; Ronald J Ellis; Benigno Rodriguez; Robert W Coombs; Giovanni Schifitto; Justin C McArthur; Kevin Robertson
Journal:  AIDS       Date:  2009-07-17       Impact factor: 4.177

Review 6.  Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  Neuropsychol Rev       Date:  2009-05-09       Impact factor: 7.444

7.  Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection.

Authors:  R A Stern; S G Silva; N Chaisson; D L Evans
Journal:  Arch Neurol       Date:  1996-02

8.  Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

Authors:  Robert K Heaton; Donald R Franklin; Reena Deutsch; Scott Letendre; Ronald J Ellis; Kaitlin Casaletto; Maria J Marquine; Steven P Woods; Florin Vaida; J Hampton Atkinson; Thomas D Marcotte; J Allen McCutchan; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Ned Sacktor; Susan Morgello; David M Simpson; Ian Abramson; Anthony C Gamst; Christine Fennema-Notestine; David M Smith; Igor Grant
Journal:  Clin Infect Dis       Date:  2014-10-31       Impact factor: 20.999

Review 9.  HIV-associated neurocognitive disorders: the relationship of HIV infection with physical and social comorbidities.

Authors:  Ellen M Tedaldi; Nancy L Minniti; Tracy Fischer
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

10.  HIV-associated neurocognitive disorder in a KwaZulu-Natal HIV clinic: A prospective study.

Authors:  Jade C Mogambery; Halima Dawood; Douglas Wilson; Anand Moodley
Journal:  South Afr J HIV Med       Date:  2017-09-26       Impact factor: 2.744

View more
  1 in total

1.  Characterization of HIV-Associated Neurocognitive Impairment in Middle-Aged and Older Persons With HIV in Lima, Peru.

Authors:  Monica M Diaz; Marcela Gil Zacarías; Patricia Sotolongo; María F Sanes; Donald J Franklin; María J Marquine; Mariana Cherner; Cesar Cárcamo; Ronald J Ellis; Serggio Lanata; Patricia J García
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.